Table 1 Baseline clinical characteristics.

From: Contemporary outcomes in no-option chronic limb-threatening ischemia

 

Pathway 1 lack of target (N = 123)

Pathway 2 non-responders (N = 57)

All patients (N = 180)

Median age

71.0 (61.0–78.0)

68.0 (61.0–76.0)

70.0 (61.0–78.0)

Male sex—no. (%)

82 (66.7%)

38 (66.7%)

120 (66.7%)

Racea—no. (%)

White

71 (61.2%)

25 (49.0%)

96 (57.5%)

Black or African Descent

39 (33.6%)

26 (51.0%)

65 (38.9%)

Asian

5 (4.3%)

0 (0%)

5 (3.0%)

American Indian or Alaska Native

1 (0.9%)

0 (0%)

1 (0.6%)

Unknown/Declined to state

7

6

13

Ethnic group*—no. (%)

Not Hispanic or Latino

110 (90.2%)

45 (84.9%)

155 (88.6%)

Hispanic or Latino

12 (9.8%)

8 (15.1%)

20 (11.4%)

Unknown/Declined to state

1

4

5

Median BMI

27.5 (23.2–30.8)

26.8 (23.0-30.4)

27.4 (23.0-30.8)

History

Stroke—no. (%)

23 (18.9%)

9 (15.8%)

32 (17.9%)

Heart failure—no. (%)

37 (31.1%)

20 (38.5%)

57 (33.3%)

Smoking—no. (%)

74 (61.2%)

31 (57.4%)

105 (60.0%)

Current

14 (11.6%)

10 (18.5%)

24 (13.7%)

Past

60 (49.6%)

21 (38.9%)

81 (46.3%)

Unknown

2

3

5

Diabetes mellitus—no. (%)

93 (75.6%)

44 (77.2%)

137 (76.1%)

Type I

6 (4.9%)

1 (1.8%)

7 (3.9%)

Type II

87 (70.7%)

43 (75.4%)

130 (72.2%)

Hypertension—no. (%)

112 (91.1%)

54 (94.7%)

166 (92.2%)

Dyslipidemia—no. (%)

91 (75.2%)

50 (89.3%)

141 (79.7%)

Hepatic insufficiency—no. (%)

3 (2.5%)

2 (3.5%)

5 (2.8%)

Renal disease—no. (%)

61 (49.6%)

31 (54.4%)

92 (51.1%)

Chronic kidney disease**

28 (22.8%)

13 (22.8%)

41 (22.8%)

End stage renal disease/dialysis

30 (24.4%)

15 (26.3%)

45 (25.0%)

Renal insufficiency

3 (2.4%)

3 (5.3%)

6 (3.3%)

Myocardial infarction—no. (%)

30 (24.6%)

17 (30.4%)

47 (26.4%)

Deep vein thrombosis—no. (%)

15 (12.2%)

7 (12.7%)

22 (12.4%)

Retinopathy—no. (%)

15 (12.6%)

3 (6.1%)

18 (10.7%)

Peripheral neuropathy—no. (%)

57 (47.5%)

21 (42.9%)

78 (46.2%)

Rutherford category—no. (%)

5

70/121 (57.9%)

36/51 (70.6%)

106/172 (61.6%)

6

51/121 (42.1%)

15/51 (29.4%)

66/172(38.4%)

Previous intervention in target limb—no. (%)

None (no-option)

45 (36.6%)

0

45 (25.0%)

1

73 (59.3%)

0

73 (40.6%)

2 or more

5 (4.1%)

57 (100%)

62 (34.4%)

Ambulatory status

No assistance needed

21 (17.1%)

6/56 (10.7%)

27/179 (15.1%)

Minimal assistance needed

20 (16.3%)

13/56 (23.2%)

33/179 (18.4%)

Walker assistance needed

32 (26.0%)

20/56 (35.7%)

52/179 (29.1%)

Wheelchair/non-ambulatory

59 (40.7%)

17/56 (30.4%)

67/179 (37.4%)

Wound status§

Open wound on limb

89/122 (73.0%)

43 (75.4%)

132/179 (73.7%)

Diagnosis of osteomyelitis

21/122 (17.2%)

12 (21.1%)

33/179 (18.4%)

Diagnosis of gangrene

58/122 (47.5%)

26 (45.6%)

84/179 (46.9%)

Treatment information

Geographic region||

South

59 (48.0%)

37 (64.9%)

96 (53.3%)

Northeast/Mid-Atlantic

50 (40.7%)

8 (14.0%)

58 (32.2%)

Midwest

10 (8.1%)

10 (17.5%)

20 (11.1%)

West

4 (3.3%)

2 (3.5%)

6 (3.3%)

Referring physician

Treating physician

78 (64.5%)

42 (75.0%)

120 (67.8%)

Emergency department

1 (0.8%)

0

1 (0.6%)

Podiatrist

13 (10.7%)

5 (8.9%)

18 (10.2%)

Specialist

21 (17.4%)

8 (14.3%)

29 (16.4%)

Other

8 (6.6%)

1 (1.8%)

9 (5.1%)

Treating physician specialty

Vascular surgery

76 (61.8%)

23 (40.4%)

99 (55.0%)

Interventional cardiology

44 (35.8%)

33 (57.9%)

77 (42.8%)

Podiatry

3 (2.4%)

1 (1.8%)

4 (2.2%)

  1. Data presented as n (%) or n (IQR).
  2. *Race or ethnic group was reported by the patient.
  3. The body-mass index is the weight in kilograms divided by the square of the height in meters.
  4. The Rutherford scale ranges from 0 to 6, with higher numbers indicating worse disease.
  5. **CKD is defined as either: (a) eGFR < 60 mL/min/1.73 m² for ≥ 3 months, with or without evidence of kidney damage, or (b) Evidence of kidney damage (e.g., albuminuria ≥ 30 mg/day, structural abnormalities, or histological changes) for ≥ 3 months, with or without reduced eGFR.
  6. §Patients could have more than 1 category of wound status.
  7. ||The South region included Florida, Louisiana, North Carolina, Puerto Rico, South Carolina, Texas, and Virginia. The Northeast/Mid-Atlantic region included Massachusetts, New Hampshire, and Washington, DC. The Midwest region included Michigan, Missouri, and Ohio. The West region included California and Colorado.
  8. Shown are Kaplan-Meier estimates for rates of amputation-free survival, limb salvage, and survival for all patients (Panel A), patients in Pathway 1: Lack of Target (Panel B), and patients in Pathway 2: Non-responders (Panel C).
  9. Shown are Rutherford Categories which range from 0 to 6, with higher numbers indicating worse disease, along with major amputation or death (Panel A), and wound status assessed as the presence of osteomyelitis, gangrene, or an open wound, along with major amputation or death (Panel B).